DAY 1

DAY 2

Speakers

Speakers

PROGRAM

2 DAYS OF HIGH LEVEL CONFERENCES

The Innovative Therapies Days will make the connection between the academic and the industrial worlds: from research, to clinical trials, to industrialisation.

CAR-T CELLS

Chimeric Antigen Receptor T cells therapy (CAR-T) has revolutionized the course of disease of patients suffering from Refractory/ Resistant Hematologic malignancies. This success has now lead the FDA and EMA to approve rapidly these innovative cellular drugs.

Based on these unexpected and impressive results, the world of cellular immunotherapy offers new perspectives.

Mix and exchanges of people from different backgrounds (academics, scientists, pharmacists, clinicians, private companies…) will provide an excellent platform to help the development of CAR-T cells in France and worldwide in order to propose these innovative drugs to patients.

CELL THERAPIES INCLUDING INDUCED PLURIPOTENT STEM CELL-DERIVED AND ENGINEERED IMMUNE CELLS

 

 

 

REGULATORY & CLINICAL TRANSFER OF INNOVATIVE THERAPIES

RNA AS RAW MATERIALS & THERAPEUTICS

Tuesday, September 20th

9:00-09:20 : Welcome and Keynote address (Kursaal conf room)

Introductive words, Sylvain Perruche, RIGHT Institute, Besançon, FR

Welcome words from the urban community’s President
Welcome words from the Region’s President

Introduction by Marco Ruella, UPENN, Philadelphia, USA 

 

9:20-12:30 : CAR-T Cells (I) (Kursaal conf room)

Chairmen: Christophe Ferrand and Marina Deschamps, RIGHT institute, Besançon, FR

09:20 :  CAR T cell function scrutinized to improve immunotherapy: Decoding the cellular interactions regulating CAR T cell antitumor activity in vivo using two-photon intravital imaging

Dr Philippe Boussot, Institut Pasteur, FR

09:50 : MNEMO THERAPEUTICS (upcoming title)

Speaker to be confirmed, USA

 

10:20 : Gold Sponsor Pitch (x2)

10:30 : BREAK

11:00 : Chinese experience and Landscape of  CART-cells in China

Pr Huang He, Bone Marrow Transplantation Center, Zhejiang University, Hangzhou 310058, China; Institute of Hematology, Zhejiang University, Hangzhou 310058, China

11:30 : Is Hospital Exemption an Alternative or a Bridge to European Medicines Agency for Developing Academic Chimeric Antigen Receptor T-Cell in Europe? Spanish public/academic experience in CART in Acute Lymphoid Leukemia and Multiple Myeloma

Dr Álvaro Urbano IspizuaHead of Hematology at the Clínic de Barcelona, Spain

12:00 : Clinical management of CART-cells in real life

Pr Roch Huo, Head of clinical Hematology, UMR INSERM U1236, Rennes, FR

12:30 : Gold Sponsor Pitch (x2)

12:35-14:00 : Lunch (Kursaal Ballroom )

14:00-16:15 : Visit of BioInnovation

13:00-16:30 : B2B Meetings

16:00-16h30 : BREAK

 

16:30-19:30 : Cell and  cell-derived  therapies   (Kursaal conf room)

Chairmen: Sylvain Perruche, RIGHT Institute, Besançon, FR

16:30 : Gold Sponsor Pitch 

16:35 : New class of cancer vaccine based on an off-the-shelf Antigen Presenting Cell line

Eric Halioua, PDC*line Pharma, Liège, BE 

17:05 : Feedback on the clinical development of cellular therapies (upcoming title)   

Dr Miguel Forte , Bone Therapeutics, Charleroi, BE

17:35 : Upcoming intervention

Speaker to be confirmed, XX, xx,xx

18:00 : BREAK

18:30 : Upcoming intervention

Speaker to be confirmed, XX, xx,xx

19:00 : Upcoming intervention

Speaker to be confirmed, XX, xx,xx

 

20:00-23:30 : Evening reception (Kursaal Ballroom)

 

Wednesday, September 21st

9:00-11:00 : Regulation, Production and CLINICAL TRANSFER OF INNOVATIVE THERAPIES (KURSAAL CONF ROOM) 

Chairwoman: Dr Mathilde Girard, ADHARA, subsidiary of the URGO Group, Chenôve, FR

09:00 : Innovation Santé 2030 plan, how France can facilitate the development of innovative therapies ? Focus on the Biotherapy – Bioproduction Integrators network 

Emmanuel DEQUIER, « Grand défi Biomedicaments »,Secretariat Général pour l’Investissement, Paris, FR

09:30 : Upcoming Title

Speaker to be confirmed, LFB Biomanufacturing, Alès, FR

10:00 : ATMP FINANCING, FROM RESEARCH TO PATIENT. (upcoming title)

Présidente ou VP to be confirmed, Jeito Capital, Paris, FR

10:30 : BREAK

11:00 : Upcoming intervention

Speaker to be confirmed, XX, xx,xx

11:30 : Upcoming intervention

Speaker to be confirmed, XX, xx,xx

12:00-14:00 : Lunch (Kursaal Ballroom )

12:30-14:00:  B2B meetings (Kursaal Ballroom)

14:00-17:00  RNA AS RAW MATERIELS & THERAPEUTICS  (Kursaal Conf room)

Chairman : Philippe DULIEU, RD Biotech, Besançon, FR

 

14:00 :Introduction on the potential of RNA, where we are and future perspectives

Pr Chantal Pichon, Center for Molecular Biophysics -UPR4301 CNRS, Orléans, FR

14:30 :  Moderna : Moderna’s mRNA platform and applications to vaccines against infectious diseases

Dr Carole HENRY, Moderna Cambridge, Massachusetts, USA

15:00 : Etherna 

 Bernard Sagaert, eTheRNA, Niel, BE

15:30 : BREAK

16:00 : INTEGRATIVE AND NON-INTEGRATIVE VECTORS (upcoming title)

Speaker to be confirmed, Flash Therapeutics, Toulouse, FR

16:30-17:00 : Upcoming Title

Dr Marco Alessandrini, Antion Biosciences , Geneva, CH

17:15-End of Congress

Join us and meet our speakers

Pr Huang He – Institute of Hematology, Zhejiang University, (Hangzhou , China), Dr Philippe Boussot – Institut Pasteur (Paris,FR), Dr Álvaro Urbano Ispizua ,  Clínic de Barcelona (Barcelona, Spain), Pr Roch Huo, UMR INSERM U1236, (Rennes, FR), Marco Ruella – Center for Cellular Immunotherapies, U Penn (Philadelphia, USA) , Eric Halioua -PDC*line Pharma (Liège-Belgium) , Bernard Sagaert – eTheRNA immunotherapies NV (Niel, Belgium)

Speakers